125I粒子植入联合其他方案治疗不可切除胰腺癌的研究进展
Progress of seed 125I implantation combined with other regimens in the treatment of unresectable pancreatic cancer
黄文鹏 1武思彤 2宋乐乐 1杨琦 1康磊1
作者信息
- 1. 北京大学第一医院核医学科,北京 100034
- 2. 北京大学第一医院介入血管外科,北京 100034
- 折叠
摘要
胰腺癌是常见的消化系统恶性肿瘤,预后较差,约80％的患者诊断时已丧失手术切除机会.在不同的治疗方案中,放射性125I粒子植入可以改善不可切除胰腺癌患者的生活质量,并有望提高其生存率.本文综述了 125I粒子植入治疗联合化疗、冷冻疗法、腔内照射、支架置入、射频消融、纳米刀、旁路手术在不可切除胰腺癌患者中的临床应用,使其更好地在临床上推广.同时有必要制定统一的剂量标准和规范指南,使其更安全、更广泛地服务于临床实践.
Abstract
pancreatic cancer is a common malignant tumor of digestive system,with poor prognosis.About 80％of patients have lost the opportunity of surgical resection when diagnosed.In different treatment schemes,radioactive seed 125I implantation can improve the quality of life of patients with unresectable pancreatic cancer and is expected to improve their survival rate.This article reviews the clinical applications of 125I particle implantation therapy combined with chemotherapy,cryotherapy,intracavitary irradiation,stent placement,radiofrequency ablation,nanoknife,and bypass surgery,in order to better promote its clinical application.However,it is necessary to establish unified dosage standards and regulatory guidelines to make them safer and more widely serve clinical practice.
关键词
胰腺肿瘤/碘放射性同位素/近距离放射疗法Key words
Pancreatic neoplasms/Iodine radioisotopes/Brachytherapy引用本文复制引用
基金项目
国家自然科学基金(82171970)
国家自然科学基金(81871385)
北京市杰出青年项目(JQ21025)
首都临床特色应用研究专项基金(Z221100007422027)
北大医学青年科技创新发展平台青年培育基金(BMU2022PY006)
出版年
2024
NETL
NSTL
万方数据